MoonLake posts Phase 2 results for sonelokimab in psoriatic arthritis and hidradenitis suppurativa

MoonLake Immunotherapeutics AG posted results for two completed Phase 2 studies of sonelokimab this week, both with adalimumab as an active comparator arm.

• Sonelokimab (M1095), Phase 2, active psoriatic arthritis: Results were posted for NCT05640245, a study that demonstrated the clinical efficacy and safety of the nanobody sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with active psoriatic arthritis¹ and included adalimumab treatment as an active reference arm¹. The trial enrolled 207 participants¹ and its primary outcome was the percentage of participants achieving an American College of Rheumatology 50% response at Week 12, defined by improvement in swollen and tender joint counts plus at least three of five other measures¹. Study completion was listed as 2024-01-15.
• Sonelokimab (M1095), Phase 2, moderate to severe hidradenitis suppurativa: Results were posted for NCT05322473, a study that demonstrated the clinical efficacy and safety of the nanobody sonelokimab administered subcutaneously compared with placebo in adult participants with moderate to severe hidradenitis suppurativa². The trial enrolled 234 participants² and its primary outcome was the percentage of participants achieving HiSCR75, a response defined by at least a 75% reduction from baseline in abscess and inflammatory nodule count with no increase in abscess or draining fistula count, at Week 12². Study completion was listed as 2023-08-30.